University of Montana

ScholarWorks at University of Montana
Graduate Student Theses, Dissertations, &
Professional Papers

Graduate School

2014

Interindividual Variability in the Cytochrome P450 3A4 Drug
Metabolizing Enzyme: Effect of the CYP3A4*1G Genetic Variant
Kasse Jean Skagen
The University of Montana

Follow this and additional works at: https://scholarworks.umt.edu/etd

Let us know how access to this document benefits you.
Recommended Citation
Skagen, Kasse Jean, "Interindividual Variability in the Cytochrome P450 3A4 Drug Metabolizing Enzyme:
Effect of the CYP3A4*1G Genetic Variant" (2014). Graduate Student Theses, Dissertations, & Professional
Papers. 4351.
https://scholarworks.umt.edu/etd/4351

This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an
authorized administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

INTERINDIVIDUAL VARIABILITY IN THE CYTOCHROME P450 3A4
DRUG METABOLIZING ENZYME: EFFECT OF THE CYP3A4*1G
GENETIC VARIANT
By
Kasse Jean Skagen
Biochemistry, Western Washington University, Bellingham, WA, 2008
Thesis
presented in partial fulfillment of the requirements
for the degree of
Master of Science in Pharmaceutical Sciences
The University of Montana
Missoula, MT
August 2014
Approved by:
J.B. Alexander Ross, Dean of The Graduate School
Graduate School
Erica Woodahl, PhD, Chair
Department of Biomedical and Pharmaceutical Sciences
Howard Beall, PhD
Department of Biomedical and Pharmaceutical Sciences
Keith Parker, PhD
Department Biomedical and Pharmaceutical Sciences
J. Stephen Lodmell, PhD
Division of Biological Sciences

Skagen, Kasse, Master of Science, Summer 2014

Pharmaceutical Sciences

Interindividual Variability in the Cytochrome P450 3A4 Drug Metabolizing
Enzyme: Effect of the CYP3A4*1G Genetic Variant
Chairperson: Erica Woodahl, PhD
Researchers and clinicians are interested in how a patient’s individual genetic
makeup could predict the appropriate medication and dose for that patient. One
way to predict drug response, or efficacy, is by looking at enzymes within the
liver that metabolize drugs. Many of these enzymes belong to a class called the
Cytochrome P450s (CYPs). Specifically, two closely related enzymes, CYP3A4
and CYP3A5, are involved in metabolizing 50% of drugs currently on the market
(eg: statins, antiepileptics, anticancer agents, and antidepressants). There can
be differences in the genetic code of these enzymes that can causes changes in
drug metabolism.
We completed a study with participants from the Confederated Salish and
Kootenai Tribes (CSKT), located on the Flathead Reservation in northwest
Montana. Select CYP enzymes were genotyped, including CYP3A4 and CYP3A5.
Most SNPs identified in the CSKT participants were found at frequencies similar
to those reported in European-descended populations. Interestingly, one specific
SNP, called CYP3A4*1G, was discovered at a high allele frequency. The
physiological significance of this SNP is unclear as there are limited and
confounding data, however, most of the data published to date suggest that the
SNP causes decreased metabolism of drugs. Clinically, this could result in a
need for a decreased dose of medication. In addition, this CYP3A4 SNP was
observed to be often inherited with another SNP in the related CYP3A5 gene,
called CYP3A5*3, which encodes a nonfunctional enzyme. These SNPs found in
the CSKT are of particular interest, because inheriting these two SNPs together
could cause drastic changes in drug metabolism since the two enzymes
metabolize many of the same drugs.
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Chapter 1: Introduction
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1.A. The Promise of Pharmacogenomics
Pharmacogenomics offers a new way of practicing medicine by individualizing
medications and dosages based on an individual’s genetic make-up [1, 2]. The
goal is to optimize efficacy while minimizing adverse events [3]. The completion
of the Human Genome Project in 2000 allowed scientists to more easily link
specific genetic changes to differences in drug response and toxicity [1, 2].

The Federal Drug Administration (FDA) states that its “mission is to protect and
promote the health of all Americans through assuring the safety, efficacy, and
security of drugs…” [4]. The FDA believes personalized medicine has potential to
increase efficacy and decrease risk of adverse drug reactions [4]. They have
released guidelines to better integrate genetic information with medications [4-6]
[3]. These are guidelines for new drug applications as well as when, how, and
what pharmacogenomic data to submit [3]. They have also required that
pharmacogenomic data be included in the product insert of 140 different
medications, many with more than one predictive biomarker; the importance of
these biomarkers can vary from drug choice, to dosage, to black box warnings [4].
Medications with pharmacogenomic data in the product insert are widespread:
trastuzumab (oncology), tamoxifen (oncology), phenytoin (neurology), warfarin
(hematology/cardiology), clopidogrel (cardiology), abacavir (infectious diseases),
atorvastatin (endocrinology), codeine (anesthesiology), and fluoxetine
(psychiatry). This information is available to the public on their website under the
Table of Pharmacogenomic Biomarkers in Drug Labeling [7]. Also in 2007, the
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FDA approved the first genotyping test, a DNA microarray, Amplichip CYP450.
This is used by physicians to assist in medication and dosage choices [8].

Another organization that releases pharmacogenetics-guided dosing
recommendations is the Clinical Pharmacogenetics Implementation Consortium
(CPIC). The CPIC was formed in 2009 and focuses on providing guidelines
designed to help providers understand how genetic test results should be used to
optimize drug therapy in clinical practice [9]. To date, they have identified 174
gene-drug pairs of interest, which include 63 unique genes and 131 unique drugs.
CPIC has published guidelines on 33 of these pairs. These 174 gene-drug pairs
are broken down into levels (A, B, C, or D) that indicate level of evidence and
strength of recommendation. Level A indicates there is evidence to change
prescribing regimen of drug, while Level D indicates there is weak or conflicting
evidence and no changes in the prescribing regimen are recommended at this
time. Codeine, phenytoin, simvastatin, and warfarin are considered Level A.
Fluoxetine, tamoxifen, and omeprazole are considered Level B. Level C drugs
include propranolol and diazepam, and Level D drugs include aspirin,
atorvastatin, caffeine, and metformin [10].

One CPIC Level A drug is tacrolimus, a medication given to patients who
undergo solid organ or hematopoietic cell transplantation to prevent rejection.
Tacrolimus has a very narrow therapeutic window and plasma levels are strictly
monitored by therapeutic drug monitoring; too little drug leads to organ or graft
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rejection while too much drug leads to nephrotoxicity [11-13]. In spite of individual
monitoring, patients still experience lack of efficacy or adverse events. The
clearance of tacrolimus is mediated by drug-metabolizing enzymes, cytochrome
P450 3A4 (CYP3A4) and 3A5 (CYP3A5), which determine drug levels in the
body. In vitro and in vivo data show that individuals with genotypes encoding for
deleterious CYP3A5 enzyme function have lower clearances and higher trough
concentrations than those expressing wildtype enzyme [14-18]. Using CYP3A4
and CYP3A5 genotypes to more accurately determine tacrolimus dosage
regimens can improve efficacy through less dosage modifications and quicker
time to target tacrolimus plasma concentrations [19].

1.A.i. Pharmacogenetics: Improving Outcomes
Most medications used today are efficacious in only 25% (oncology medications)
to 80% (analgesic medications) of patients [4, 20]. Although efficacy can be
affected by several factors such as patient compliance, diet, and drug
interactions, genetic variations can play a large role [3]. Identifying patients at risk
for adverse events can help to minimize injuries as well as reduce medical costs.
Adverse drug reactions (ADRs) refer to significant side effect(s) of medications,
some of which can be life threatening [21-23]. The Institute of Medicine reports
that there are at least 1.5 million preventable ADRs in the United States (US) per
year and they are considered the leading cause of preventable death [24, 25]. As
a result of ADRs, there are more than 100,000 deaths per year in the US costing
$100 billion per year [26]. Pharmacogenomics may be able to play a role in
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reducing these adverse events by predicting those at higher risk due to a change
in drug metabolism.

Interindividual variability in drug response and toxicity is multifactorial and include
both extrinsic and intrinsic factors. Extrinsic factors include the environment (i.e.
smoking, diet, and alcohol consumption) and drug interactions (i.e. concomitant
use of other prescription medications, over-the-counter medications, and herbal
supplements). Intrinsic factors include demographics (age, gender, and ethnicity)
and disease (particularly liver and kidney dysfunction). Finally, genetic variation
between individuals can also be a key player in differences in response and
toxicity [27-30]. It has been proposed that genetic factors can account for as
much as 20-95% of interindividual variability in drug disposition [31]. This wide
estimation accounts for different effects of genetic factors in different gene-drug
pairs. The amount of interindividual variability can be drug specific; it will affect
metabolism rates differently depending on the drug given. Also, drug elimination
pathways can be very complex, causing genetic factors to have different effects.

1.A.ii. Genotype-Phenotype Associations
Genotype-phenotype association studies are important in order to make a
prediction about how a patient’s genetic variation, or their genotype, can affect
the response or toxicity to a given medication, known as their phenotype. Genetic
variation can affect the outcome of about a quarter of all medications [29]. It is
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important to identify individuals carrying these variations so that alternative
medications or doses may be chosen.

Most genotype-phenotype correlations can be measured through in vivo or in
vitro probe drug assays [32]. Probe drugs are metabolized by a single drugmetabolizing enzyme and are administered to identify the function of that enzyme.
Phenotypes can be measured through administration of a subtherapeutic dose of
probe drug [33]. When using probe drugs to measure a phenotype, plasma and
urine concentrations of the parent drug and metabolite are measured in order to
estimate the pharmacokinetics of the parent and metabolite(s) [33, 34]. An
advantage of this method is that phenotype is directly measured under current
conditions (diet, age, disease state, etc). However, there are several
disadvantages. This method can have complicated protocols and there is a risk
of determining the wrong phenotype to do concurrent medications or disease
state. There is also a risk of an ADR in patients of extreme phenotypes [34].
However, in clinical practice, phenotype is typically measured by a clinical
outcome (i.e. INR for warfarin or reducing LDL levels for statins) [35].

There are four phenotypes: Poor Metabolizers (PM), Intermediate Metabolizers
(IM), Extensive Metabolizers (EM), and Ultra Metabolizers (UM). PMs do not
express active enzyme. This can cause increase risk of toxicity if the medication
is toxic but decreased efficacy if metabolite is active. IMs have reduced enzyme
activity. These patients continue to have lower metabolism than the standard
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population. EMs express fully active enzyme and standard doses are given to
these patients. UMs have multiple copies of functional enzyme. These patients
may have increased risk for toxicity if the metabolite is toxic or decreased
efficacy if the parent medication is active [8, 33, 34, 36].

Genotyping allows practitioners to optimize the drug choice and dose for each
individual and avoid most ADRs. These can lead to decreased medical costs [34].
Genotyping can have the largest clinical impact on patients taking narrow
therapeutic medications, patients with unexplained side effects, as well as, older
patients. Older patients tend to take more medications and are more likely to
exhibit serious side effects; they also can display large changes in metabolism
due to decreased liver and kidney function [37].

1.A.iii. Sources of Genetic Variability in Drug Response and Toxicity
Pharmacogenetic variability results from genetic variation in both
pharmacokinetic and pharmacodynamic properties of a drug. Pharmacokinetics
is the study of the effect of the body on drugs, while pharmacodynamics is the
study of the effects of drugs on the body. Alterations in pharmacokinetic
pathways alter the drug exposure in an individual and make up the vast majority
of pharmacogenetic variability.

The pharmacokinetic disposition of a xenobiotic can be broken down by the
processes of absorption, distribution, metabolism, and elimination (ADME) [38].
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Absorption describes the processes that control the rate and extent of absorption
of a compound from the site of administration to the systemic circulation. These
processes include passive diffusion (small, lipophilic xenobiotics), active or
facilitated transport (large, polar, or charged xenobiotics), and first-pass
extraction in the gastrointestinal tract and liver for drugs that are orally
administered [39]. After xenobiotics have entered systemic circulation, they are
distributed from the vasculature to various tissues of the body, including those
where they exert pharmacologic, and perhaps toxic, effect. The extent of this
distribution depends upon passive and active diffusion rates across membranes
and protein binding in both blood and tissues [38]. Metabolism mainly occurs in
the liver, however, other tissues are known to have some metabolism such as
kidney, lungs, and intestines [40]. Substrates undergo a wide range of metabolic
reactions. Most undergo Phase I metabolism where the substrate undergoes
oxidation, reduction, or hydrolysis reactions. Next, drugs often undergo
sequential Phase II metabolism, which are conjugative reactions [38]. Hepatic
metabolism is a primary component in the clearance of many compounds.
Metabolism also plays a large role in first-pass extraction in the intestine and liver
and, consequently, has a large effect on bioavailability of compounds that are
extensively metabolized [38, 41]. Elimination of xenobiotics includes both the
processes of metabolism and excretion. The primary routes of excretion are
biliary excretion, via transporters, in the liver [42] and urinary excretion in the
kidneys, by glomerular filtration and passive and active secretion via transporters
[38, 43].
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Phase I enzymes are made up of mostly heme thiolate proteins called
cytochrome P450s (CYPs) that facilitate hydroxylation, reduction, and oxidation
reactions to convert lipophilic compounds to more hydrophilic compounds that
are more easily excreted [34, 37, 44, 45]. These enzymes metabolize a wide
variety of medications, steroids, fatty acids, and procarcinogens [46]. Examples
of CYPs are CYP1A2, CY2C9, CYP2C19, CYP2D6, and CYP3A4 [38]. Phase II
enzymes are conjugative by taking advantage of the hydrophilic groups added by
Phase I enzymes. These conjugative reactions are mainly glucuronidation,
sulfation, acetylation, and methylation. Examples of these enzymes are UDPglucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione Stransferases (GSTs) [34, 37, 38]. Drug transporters are important in transporting
hydrophilic drugs, metabolites, and conjugated metabolites across cell
membranes and facilitating their elimination in the bile and urine. Drug
transporters are also important in mediating delivery of drugs or their metabolites
to their therapeutic target. Important examples of drug transporters are Pglycoprotein (P-gp), multidrug resistance-associated proteins (MRPs), organic
anion transporters (OATs), organic cation transporters (OCTs), and organic
anion transporting polypeptides (OATPs) [34, 47, 48].

Genetic variation in drug-metabolizing enzymes and drug transporters are of key
importance in pharmacogenomics. A variety of genetic modifications can cause
alterations to these proteins, including gene deletions and duplications, known as
copy number variation (CNV), insertions and deletions, as well as point mutations,
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known as single nucleotide polymorphisms (SNPs). A polymorphism is defined
as a genetic mutation that is present at a frequency of greater than 1% [34].
Genetic variation can occur in coding (exons) or noncoding (introns, 5’UTR and
3’UTR) regions [3].

1.B. Cytochrome P450s
The cytochrome P450 family is the most important class of enzymes in overall
drug metabolism, accounting for 78% of metabolism of drugs cleared through the
liver [49]. The Human Genome Project has identified 57 active enzymes and 58
pseudogenes [37, 50-52]. CYPs are a superfamily of hemeproteins, which are
found in the smooth endoplasmic reticulum (ER) membrane. These enzymes
have two main roles: metabolize exogenous drugs and xenobiotics as well as
metabolize hormones, vitamins, and fatty acids [53]. They are expressed in
several extrahepatic tissues including the intestine, lung, kidney, and brain but
are preferentially expressed in the centrilobular area of the liver [34, 37, 54].
“Cyto” refers to microsomal vesicles while “chrome” refers to color. The “P”
alludes to the pigmentation, red, conferred by the heme, and 450 refers to the
maximum absorbance of 450 nm when the enzyme is bound to carbon monoxide
[8, 36, 37, 55, 56].

There are 16 human families of CYPs [33, 34, 36, 55]. A family is defined as
enzymes that have ≥40% amino acid identity and are designated by a number.
Families are divided into subfamilies that have ≥ 55% amino acid identity and are
designated by a number. Finally, numbers are given to designate different genes
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[36, 37, 55, 57]. There are 3 major groups of CYPs: 1) CYP1-3 families have
lower affinity for substrates and are less conserved but are responsible for 7080% of all Phase I metabolism 2) CYP4 family metabolizes fatty acids and some
xenobiotics and 3) CYP5-51 families have high affinity for endogenous
substrates and are relatively well conserved [34, 37].

1.B.i. CYP Evolution
The first cytochrome is believed to have arisen less than 3.5 billion years ago
and to have functioned anaerobically [58, 59]. Since then, CYPs have undergone
multiple rounds of expansion facilitated by gene duplication. The first round
occurred around 1.5 billion years ago. This expansion gave rise to CYPs that
metabolized fatty acids and cholesterol [60]. The next expansion occurred
around 900 million years ago. This resulted in CYPs that metabolize steroids.
One of these CYPs later gave rise to current day CYP families 1 and 2. Finally,
400 million years ago, CYPs underwent another round of expansion. This
resulted in several CYP families that metabolize xenobiotics. This last expansion
is thought to be driven by aquatic organisms vast change in diet upon
introduction onto land as well as terrestrial organisms introduction to combustion
products [61, 62].

Despite multiple distinct rounds of expansion, most CYP families are
continuously changing. Gene duplication allows for one copy to diverge while the
other copy maintains its original function. This often creates a pseudogene,
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however it sometimes increases the overall fitness of the organism. For example,
CYP often arose by metabolizing toxic substances from organisms’ diets [62].
Because CYPs are beneficial in order to process a wide variety of changing
toxins, they have become a rapidly evolving gene. Change in a gene is
measured by length of time for a unit of evolutionary period. CYPs unit of
evolutionary period is about 2 – 4 million years. However, histones unit of
evolutionary period is about 400 million years while immunoglobulins are about
700,000 years [61, 62].

1.B.ii. CYP Structure and Conserved Regions
Most CYPs have around 480 to 560 amino acids. They can be categorized into
three groups based on location: 1) ER membrane (microsomal-type) 2)
mitochondrial membrane (mitochondrial-type) or 3) cytosol (rare in eukaryotes)
[57]. Microsomal CYPs are differentiated by their signal-anchor sequence,
located at the N-terminal, which targets the enzyme to the endoplasmic reticulum
membrane. This signal domain is made up of 20-25 hydrophobic residues and is
distinguished by charged residues on either side, basic residues toward the Cterminal and negative residues near the N-terminal. These charged residues
ensure that the CYP is properly inserted into the membrane, luminal side of the
ER with enzyme exposed to cytoplasm. The hydrophobic region serves as the
stop-transfer sequence [57, 63-65]. However, mitochondrial CYPs have a
mitochondria-targeted sequence instead. This sequence acts to stall the folding
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of the catalytic site until enzyme is transported into the mitochondria where it is
then cleaved [57].

Although the CYP superfamily share only 20% sequence identity, they do share
overall folding and topology [66]. They have an alpha helix rich carboxy-terminal
and a beta-sheet rich amino-terminal [46]. Parallel helices (D, L, and I) as well as
antiparallel helix (E) make up the common structure [67]. The heme binds
between helix I and L to the Cys-heme-ligand loop containing the sequence,
FxxGx(H/R)xCxG; the cysteine is essential as if forms the fifth ligand to the heme
[68, 69]. Helix I is located near the center of the enzyme and within the heme
pocket. It contains the conserved sequence (G/A)Gx(D/E)T. The threonine
residue is part of the oxygen-binding pocket and is involved in catalysis [70-72].
Another conserved sequence, EXXR, is located in helix K. This sequence is key
for enzyme function [69].

There are six substrate recognition sites located within helices F, G, and I [73].
These sites affect substrate specificity and are flexible to accommodate better
substrate binding [74]. Any genetic changes that alter amino acid residues within
regions can cause changes in drug affinities and metabolism [73].

1.B.iii. CYP Biochemistry and Catalytic Cycle
CYPs oxidize various toxins, medications, and endogenous substrates.
Mechanistically, these enzymes split molecular oxygen to incorporate one as a
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functional group on the substrate while the other is released as a water molecule.
This reaction requires an electron donor, the reducing agent NADPH. The
general formula is NADPH + O2 + SH + H+ -> NAD(P)+ + SOH + H2O [46]. Figure
1.1 illustrates the general CYP catalytic cycle. CYPs remain in an unreactive
state until binding of the substrate. The first step is a transfer of an electron from
cytochrome P450 reductase to reduce the iron from 3+ to 2+ charge. Next, the
CYP complex binds molecular oxygen and triggers another electron transfer from
either cytochrome P450 reductase or cytochrome b5. Two protons are accepted
and the iron returns to a 3+ state. Finally, an oxygen atom is transferred to the
substrate. The oxidized substrate is then released [75, 76]. There are three
abortive steps (Figure 1.1), called uncoupling, within this cycle that return the
enzyme to its resting state. Each produce either a superoxide anion, hydrogen
peroxide, or water and occur at different intermediate states [77].

1.B.iv. CYP Regulation
There are four different types of CYP regulation: xenobiotic-inducible [78], sexspecific, tissue-specific [79], and developmental [80] regulation. CYP induction
is an important mechanism in protecting an organism from changing toxins. For
example, phenobarbital is a known broad CYP inducer [78, 81]. There are three
receptors present in the cytosol that detect toxins. The pregnane X-receptor
(PXR) regulates CYP2C9 and CYP3A4 [82-85], the aryl hydrocarbon receptor
(AhR) regulates CYP1A1 and CYP1A2 [86], while constitutive androgen
receptor (CAR) regulates CYP2C9 and CYP3A4 [82-85]. There have been
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polymorphisms reported in all three of these receptors that effect CYP
expression [87]. CYPs are also regulated in a sex-specific manner through the
endocrine system and gonadal hormones. The endocrine system also plays a
role in tissue-specific regulation [88].

1.C. Academic-Community Research Partnership with the Confederated
Salish and Kootenai Tribes
The Confederated Salish and Kootenai Tribes (CSKT) are located in northwest
Montana on the Flathead Indian Reservation. Three tribes reside on this
reservation as part of CSKT: the Bitterroot Salish, Upper Pend d’Oreille, and
Kootenai. Our laboratory is involved in a research partnership with CSKT to
explore the use of pharmacogenomics within the tribe. With personalized
medicine on the rise, some populations with health disparities are not always
included in research, and therefore, do not benefit from gene-guided therapies.
There is little known about pharmacogenomic variation within understudied
populations, like American Indian populations. Because allele frequencies are
diverse among world populations, allele frequencies within American Indians
cannot be assumed to be similar to other studied populations [89, 90]. It is
important to investigate frequencies of genetic variants in all populations in order
to utilize pharmacogenomic testing.

Members of our laboratory have met with Tribal Council, Tribal Health, and a
community advisory board to assure there is proper approval before any

	
  

15	
  

research began. The community stated their main interest was in anticancer
pharmacogenomics, mainly tamoxifen. CYP2C9, CYP2D6, CYP3A4, and
CYP3A5 are responsible for 75% of all phase I drug metabolism, including
several other anticancer agents. Therefore, our laboratory analyzed blood
samples from tribal volunteers to explore the genetic variation with CYP2C9,
CYP2D6, CYP3A4, and CYP3A5. Research participants, 18 years and older,
were recruited at powwows, health fairs and career fairs and were asked tribal
affiliation and blood quanta. DNA was extracted from whole blood and CYP2D6
(entire gene) was resequenced in 187 participants, while CYP2C9, CYP3A4, and
CYP3A5 (exons and flanking intron regions) was resequenced in 94 random
participants [90].

1.C.i. CYP2C9 Resequencing
CYPC9 makes up 20% of hepatic CYP content and metabolizes about 15% of
medications currently on the market, several with narrow therapeutic windows.
Table 1.1 lists common substrates, inducers, and inhibitors for CYP2C9.
Examples of substrates are warfarin, ibuprofen, and phenytoin [3, 36, 37, 46].
There are two important variants of CYP2C9, CYP2C9*2 and CYP2C9*3 (Table
1.2) that can cause large interindividual variability as well as cause adverse
events [91, 92]. Together, these alleles are in seen in about 18% of European
descendants, but much less so in other populations (Table 1.3). CYP2C9*2 and
CYP2C9*3 encode for proteins with reduced intrinsic clearance. This effect is
substrate specific but can caused reduced activity up to 90% [92, 93].
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In resequencing CYP2C9 in the CSKT population, our laboratory found 41 SNPs,
11 novel (most with very low frequencies). Also CYP2C9*2 and CYP2C9*3 were
found to at a frequency lower than those found in European descendants. These
SNPs cause decrease function but, due to their low frequencies, may play a
minor role in CYP2C9 interindividual variability in the CSKT. Also, low level of
linkage was seen between CYP2C9 SNPs. Table 1.3 lists the allele frequencies
of interesting SNPs identified in the CSKT population.

1.C.ii. CYP2D6 Resequencing
CYP2D6 is another important drug-metabolizing enzyme in the CYP2 family.
There are several polymorphisms of CYP2D6 that can cause a large clinical
impact (Table 1.4). Although it only makes up two percent of total hepatic CYP
content, it takes part in the metabolism of 15% of drugs on the market. CYP2D6
metabolizes several different substrates: propranolol, paroxetine, trazodone,
codeine, and fentanyl (Table 1.1) [46, 49]. CYP2D6 is the only non-inducible
CYP, so genetic variation accounts for much of the interindividual variability [49,
94]. There are more than 80 known variants, which could drastically change
metabolism [95]. PMs are more common in Caucasians with 5-10% expressing a
null allele. However, only 0-1% of Africans and Asians are classified as PMs. The
most common allele responsible for the PM phenotype is CYP2D6*4. IMs are
more common in Asians with 50% expressing the CYP2D6*10 allele. Only, 1015% of Caucasians are classified as IMs, expressing the CYP2D6*41 allele,
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encoding for a SNP that causes a fraction to missplice, and 30% of Africans
express the CYP2D6*17 allele. UMs are more common in African populations.
The frequency of gene duplications is present in up to 50% in some populations
and can cause up to 30-fold higher amounts of metabolite [94, 96]. It is thought
that gene duplications evolved as a result of dietary pressure [94].

Upon resequencing CYP2D6 in the CSKT population, our lab found 76 SNPs
with 9 identified as novel. Individuals with multiple copies of CYP2D6 were found
to be low in this population (1.34% of alleles). The major SNPs were found to be
at similar frequencies found in Caucasians (Table 1.5); 1.1% are UM, 87.2% are
EM, 3.2% are IM, and 5.9% are PM. However, there was a high level of linkage
seen between CYP2D6 SNPs, including several novel haplotypes identified. The
functional consequences of these haplotypes are unclear.

1.C.iii. CYP3A4 and CYP3A5 Resequencing
CYP3A4 is the highest expressed CYP in the liver and intestine, making up to
60% of total hepatic CYP expression [97]. Also, its presence in the small intestine
is a large factor of first-pass effect [98]. CYP3A4 metabolizes a large range of
substrates, totaling more than 120 different medications (Table 1.1), such as
midazolam, saquinavir, erythromycin, diazepam, verapamil, tacrolimus, and
simvastatin. CYP3A4 also metabolizes procarcinogens and endogenous
substrates like testosterone and progesterone [99].
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Most variants within CYP3A4 occur at a frequency of less than 5% and rarely
occur has homozygotes, [30, 32, 100-105] although, not all have been well
characterized. Figure 2.2 shows a map of the exons and introns of CYP3A4 with
relative locations of major SNPs.

CYP3A4*1B has been identified in the 5’UTR, however, there is confounding
data as to its clinical effect. Some investigators report this SNP causes
decreased nuclear protein binding [106] and its presence has been linked to
different diseases such as prostate cancer [107, 108]. However, in vivo and in
vitro data using probe drugs are not so clear. Using a luciferase expression
assay, investigators report an increased rate of expression for the CYP3A4*1B
allele [109, 110]. Although not significant, it has also been reported that human
livers expressing this SNP have an increased rate of nifedipine metabolism.
However, other in vitro and in vivo studies show no such association between
genotype and phenotype [101, 111, 112].

Coding SNPs seem to be more localized within exons 5-7 and 11-12 and
frequencies are reported to be low (<5%). Most SNPs result in minimal, if any,
change in drug metabolism. Those that do change enzyme activity, appear to do
so in a substrate dependent fashion. CYP3A4*2 causes decreased clearance
and a 6-fold increase in the Km in nifedipine metabolism, however, no change in
the metabolism rate of testosterone [102, 113]. CYP3A4*3 encodes for a SNP
within the heme-binding pocket, although, no change in clearance is observed
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[103, 104, 114]. CYP3A4*8 and CYP3A4*13 are reported to have low protein
content in a cells and are expected to cause decreased levels in vivo [103, 104].
CYP3A4*12 results in an increased clearance of testosterone 15β and 2βhydroxylation [103]. CYP3A4*17 is reported to cause a reduction in testosterone
metabolism while CYP3A4*18 causes an increase in testosterone metabolism
[104].

Intronic SNPs are more rare and are mostly present at a frequency of less than
1%, however, a few are reported at much higher frequencies. G20338A and
T15871C are present at approximately 50% in African American and 6.5% in
Caucasians. Interestingly, these two alleles are commonly inherited together in
African Americans, although no clinical significance has been reported [100].
CYP3A4*1G is another SNP, located in intron 10, seen at higher frequencies in
various populations [115]. There is mixed data, although, most suggest
decreased clearance [116-120]. CYP3A4*22, located in intron 6, is found in
Caucasian populations [121, 122]. Again, this SNP has mixed data, however,
most suggest it leads to decreased clearance [122-126].

Resequencing CYP3A4 in CSKT populations resulted in identification of 15 SNPs,
of which 4 are novel SNPs. Major SNPs identified are listed in Table 1.6. All
SNPs were seen with frequencies similar to Caucasians, except for CYP3A4*1G,
seen with a frequency similar to Japanese and Chinese populations (26.8%)
(Table 1.7). This results in 7% of individuals with the homozygous,
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CYP3A4*1G/*1G genotype, and 39% as heterozygous for *1G. This SNP has
conflicting data as to its clinical relevance and will be discussed in section 1.C.v.

CYP3A5 is expressed in the liver, and is the only CYP3A isoform expressed
outside the liver and intestine tissues, such as the kidney [127], prostate [128],
and lung [129, 130]. CYP3A5 has a similar structure to CYP3A4 and metabolizes
many of the same substrates, however, it usually does so with slower turnover
rates [131, 132]. Because CYP3A4 and CYP3A5 have similar substrates, there is
no known specific substrate of CYP3A5. This makes it difficult to measure
CYP3A5 specific activity [129].

Polymorphisms with the largest clinical impact can be divided into coding region
variants and intronic SNPs that cause frameshifts or splicing defects [129].
Figure 2.2 shows a map of introns and exons and the location of the major SNPs.
SNPs have been reported within the 5’ untranslated region, CYP3A5*1B and
CYP3A5*1C, however, they are seen to have no clinical significance [100, 133].
CYP3A5*6, *7, *8, *9, and *10 are all SNPs within the coding region that result in
change in enzyme function. CYP3A5*6 results in a truncated, nonfunctional
protein [100, 129]. CYP3A5*7 actually encodes for a base insertion that causes a
frameshift, and again, a nonfunctional protein [129, 133, 134]. CYP3A5*8 and
CYP3A5*9 encode for amino acid changes that result in roughly 50% enzyme
activity. CYP3A5*10 results in an inactive enzyme through an amino acid change
in the heme-binding region [129].
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CYP3A5*3 and CYP3A5*5 are clinically important intronic SNPs [129].
CYP3A5*3 is the most common polymorphism seen in CYP3A5. This intronic
SNP causes a splice variant with integration of a portion of intron 3. This leads to
a frameshift and premature termination. This deleterious SNP is more commonly
found in Caucasians and Asians, however, Africans more often express the
functional, wild-type, enzyme [100, 133]. CYP3A5*5 causes a change in a base
in the splicing donor site and results in truncated protein [129, 134].

Resequencing of CYP3A5 in CSKT populations resulted in identification of 10
SNPs; 1 was novel and found at a low frequency. Other major identified SNPs
are listed in Table 1.8. CYP3A5*3 was found at frequency of 92.47%, similar to
Caucasians (Table 1.9). This results in 86% of the CSKT population as
homozygous for CYP3A5*3, 14% are heterozygous individuals, and zero were
homozygous for CYP3A5*1 (wild-type).

Overall, CYP3A4 and CYP3A5 exhibit a high level of linkage. However, there
was a break in the linkage between CYP3A4*1G and CYP3A5*1 (0.158 LD). The
clinical relevance of this linkage will be explored in following section, Implications.

1.C.iv. Implications
Despite novel SNPs found in CYP2C9, CYP2D6, CYP3A4, and CYP3A5, they
are not expected to play a large role in interindividual variability because of their
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low frequencies. Most common allele frequencies were found to be similar to
those found in Caucasians. Although, one SNP, CYP3A4*1G, was found at a
much higher frequency. CYP3A4*1G frequency is much more similar to
Japanese and Chinese populations. However, unlike all other populations where
CYP3A4*1G is found in high linkage with CYP3A5*1, CSKT has a novel break in
the linkage between CYP3A4*1G and CYP3A5*1. In combination, the relatively
common CYP3A4*1G (26.81% allele frequency) and the high frequency
CYP3A5*3 (92.47% allele frequency) in the CSKT could have large clinical
implications because CYP3A4*1G data suggest lower activity [116-120] and
CYP3A5*3 encodes for a nonfunctional protein [100, 133]. Individuals carrying
CYP3A4*1G and CYP3A5*3 could have severely diminished CYP3A activity.

1.C.v. CYP3A4*1G Data
CYP3A4*1G is an intronic SNP found within intron 10 [135]. Again, most data
suggest diminished activity for CYP3A4*1G. There have been several studies
investigating the effect of CYP3A4*1G on fentanyl consumption post
gynecological surgery [116, 117, 119, 120]. Zhang et al. found a trend of
decreased fentanyl consumption for CYP3A4*1G carriers [119], while Dong et al.
found a statistical difference of decreased fentanyl consumption between only
CYP3A4*1G/*1G status with both the heterozygote and wild-type [117]. Zhang et
al., interestingly, found a significant decrease in fentanyl consumption for patients
carrying both CYP3A4*1G/*1G and CYP3A5*3/*3 [116]. This haplotype is seen in
high frequency within the CSKT and could change their drug metabolism. More
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recently, Yuan et al. analyzed the effect of CYP3A4*1G on fentanyl consumption
as well as plasma concentrations [120]. They found that patients who expressed
CYP3A4*1G/*1G had statistically higher fentanyl plasma concentrations and
required lower fentanyl doses than those who expressed heterozygote or wildtype genotypes. All patients in all studies were female; CYP3A4 genotype could
have a higher impact on females, because they are reported to express more
CYP3A4 [136]. With higher metabolism rates due to more protein content,
changes in activity can results in larger changes in metabolism rates.

A trend of decreasing function of CYP3A4*1G was found when investigating its
effect on atorvastatin efficacy [118]. A gene-dose effect was found on the mean
reduction of serum total cholesterol after atorvastatin treatment. However, this
effect was not seen after simvastatin treatment, suggesting potential substratespecific effects.

There are also a few studies that suggest CYP3A4*1G is a gain-of-function SNP.
Miura et al. found that tacrolimus pharmacokinetics were significantly altered in
patients carrying CYP3A4*1G and were CYP3A5 expressers; these patients had
lower exposures and initial concentrations [137]. Zuo et al. also found this same
effect. Patients carrying CYP3A4*1G and CYP3A5*1 had the highest tacrolimus
clearance than other haplotypes. Also, CYP3A4*1G carriers and CYP3A5
nonexpressers also had higher clearance than those expressing CYP3A4*1/*1
and CYP3A5*3/*3 [138]. He et al. investigated the effect of CYP3A4*1G on
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coronary heart disease (CHD) risk. Using a multivariate regression, they found
that those who express CYP3A4*1G/*1G are at increased risk of CHD. The
authors suggest that CYP3A4*1G is a gain of function. They argue that because
CYP3A4 metabolizes estrogen, and estrogen is protective against CHD, that
those who carry CYP3A4*1G must metabolize estrogen more quickly [139].
However, no probe drugs were used to actually assay CYP3A4*1G clearance.
Another study, looking at CYP3A4*1G effect on risperidone metabolism, found
no significant difference between plasma risperidone concentrations [140].
However, those expressing CYP3A4*1G/*1G did have much lower plasma levels.
This study performed a Kruskal-Wallis analysis between all three genotypes
groups. As in other studies, perhaps they would have found significance if they
had grouped CYP3A4*1/*1 with CYP3A4*1/*1G and analyzed their plasma
concentrations with CYP3A4*1G/*1G. Because risperidone is mainly metabolized
by CYP2D6, the authors suggest that changes in CYP3A4 function would be of
greater impact in those who are CYP2D6 poor metabolizers. CYP2D6 was not
genotyped, which again, may have resulting in CYP3A4*1G significance when
CYP2D6 genotype was accounted for.

The combined data suggest a possible substrate-dependent effect of
CYP3A4*1G. However, most data do indicate CYP3A4*1G results in decreased
clearance. More research needs to be done to identify the effect of CYP3A4*1G
as well as when inherited with CYP3A5*3/*3.
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1.D. CYP3A Subfamily
The CYP3A subfamily comprises four functional genes, CYPs 3A4, 3A5, 3A7,
and 3A43, as well as two pseudogenes [129, 141]. All six genes are located
inline with one another on chromosome 7 [129]. This subfamily shares many
substrates but differ in tissue expression [34, 46, 129]. CYP3A4 metabolizes
around 50% of drugs currently on the market and could, therefore, be considered
one of the most important drug metabolizing enzymes (Table 1.1) [3, 34, 36, 46,
129, 142-144]. Common SNPs in CYP3A5 encode for deleterious protein and,
therefore, is variably expressed. CYP3A7 is expressed in fetal livers up until
about 6 months of age. However, 10% of adult livers continue to express
CYP3A7 and can contribute up to almost a quarter of total CYP3A content, which
can contribute to clearance [145-147]. CYP3A7 expression into adulthood exists
more in Japanese populations, with 3A7 accounting for up to 40% of 3A content
[147]. CYP3A43 has been found in several tissues, however, at very low
quantities. Also, it exhibits reduced activity towards testosterone, so it is not
expected to play much of a role in xenobiotic metabolism [148].

1.D.i. CYP3A4
The CYP3A4 gene is 27kb and includes 13 exons and 12 introns. The gene
encodes for a 57 kDa protein made up of 502 amino acids [57, 89, 149, 150].
Substrates of CYP3A4 are large and lipophilic [49]. CYP3A4 can metabolize a
wide range of structural substrates due to its large and flexible binding pocket
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[151, 152]. It has been known to bind multiple substrates at once which can
cause increased or decreased product formation [153].

1.D.ii. CYP3A4 Variability
It has been estimated that 90% of CYP3A4 interindividual variation is due to
genetic factors [154]. Variability in CYP3A4 expression can cause a dramatic
clinical effect due to the large number of substrates [30]. There is large
interindividual variability seen in CYP3A4 expression, up to a 40-fold change
[112, 155, 156]. However, most populations tend to lie within a 4- to 6-fold
variation [106, 156-158]. Genetic variants do not account for all the variability,
however, there are numerous factors that need to be considered [34, 129]. There
have been over 20 variants reported that can explain for some variation. Also,
CYP3A4 can be induced, through increased transcription, by certain xenobiotics,
such as rifampicin, barbiturates, carbamazepine, glucocorticoids, and St. John’s
Wort [34, 36, 46, 159]. CYP3A4 can also be inhibited by various xenobiotics.
Ketoconazole, saquinavir, fluoxetine, and grapefruit juice have been reported to
as inhibitors. Potent inhibitors can cause plasma levels of the drug to increases
20-fold [34, 36, 160]. CYP3A4 is the only P450 that is expressed at different
levels between sexes, with women expresses up to 2-fold more protein than men
[136]. Finally, some interindividual variation may exist due to hormonal regulation
of CYPs. Hormones can be endogenously circulating or present in diet [28]. All
these factors can make determining genotype-phenotype correlations difficult.
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1.D.iii. CYP3A4 Phenotypes
Phenotypes seen from variation in CYP3A4 are unimodal, unlike what is seen in
CYP2D6. In vivo treatment with midazolam resulted in outliers exhibiting higher
clearances [158]. However, when treated with nifedipine, outliers were present
with lower clearances [161]. This unimodal distribution suggests that no single
factor can be used to predict CYP3A4 phenotype [30].

1.D.iv. CYP3A5
CYP3A5 has 13 exons and is made up of 502 amino acids [32, 162]. Unlike
CYP3A4, CYP3A5 is not markedly induced [163]. However, CYP3A5 is
polymorphic with the most common SNP encoding for deleterious protein [164].

1.D.v. CYP3A5 Phenotypes
In individuals who express wild-type CYP3A5 enzyme, CYP3A5 can make up
50% of CYP3A content [100]. This can result in large interindividual variability in
CYP3A metabolism; those carrying the CYP3A5*3/*3 genotype metabolize
midazolam at less than half the rate of those carrying at least one CYP3A5*1
functional allele [100, 156]. Due to the dramatic decrease in activity, CYP3A5
genotype has been correlated with statin treatment side effects[165].

1.D.vi. CYP3A4 and CYP3A5 Linkage Disequilibrium
CYP3A4 and CYP3A5 are found in a high degree of linkage disequilibrium in
Caucasian and Asian populations with the most common haplotype being
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CYP3A4*1 and CYP3A5*3 [3]. Caucasians also exhibit linkage disequilibrium
between CYP3A4*1B and CYP3A5*1 [100, 106]. It is hypothesized that the two
haplotypes could result in similar activity; the two alleles compensate for one
another. African populations have very diverse haplotypes with no significant
degree of linkage disequilibrium seen [3], however, they are more likely to carry
both the CYP3A4*1B and the CYP3A5*1 alleles [100, 166].

1.E. Specific Aims
The objective of this project is to determine the functional consequence of the
CYP3A4*1G genetic variant using in vitro methods. The specific goals of Aim 1
was to use immortalized human lymphocytes with differing CYP3A4 genotypes
(CYP3A4*1/*1, CYP3A4*1/*1G, and CYP3A4*1G/*1G) to analyze the effect of
CYP3A4*1G on relative mRNA content, protein content, and enzyme activity.
Aim 2 used human liver microsomes to, again, determine the effect of
CYP3A4*1G on protein content and enzyme activity.
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Table 1.1. List of CYP2C9, CYP2D6, and CYP3A4/5 Common Substrates,
Inhibitors, and Inducers
CYP2C9

CYP2D6

CYP3A4/CYP3A5

Substrates
ibuprofen
phenytoin
tolbutaminde
S-warfarin

Inhibitors
amiodarone
fluconazole
fluvoxamine
fluoxetine
sulfaphenazole

atomexetine
bufuralol
debrisoquine
desipramine
dextromethorphan
buspirone
erythromycin
felodipine
dextromethorphan
lovastatin
midazolam
nifedipine
simvastatin
terfenadine
testosterone
triazolam

bupropion
fluoxetine
paroxetine
quinidine
azamulin
clarithromycin
erythromycin
fluconazole
grapefruit juice
indinavir
itraconazole
ketoconazole
ritonavir
saquinavir
troleandomycin
verapamil

Inducers
rifampin

carbamazepine
phenytoin
rifampin
St. John’s wort

This list is not intended to be inclusive. Adapted from FDA website “Drug Development
and Drug Interactions: Table of Substrates, Inhibitors and Inducers.”
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Table 1.2. Major CYP2C9 Alleles
Allele
Nucleotide Change Protein Change
CYP2C9*2 (rs1799853)
430C>T
R144C
CYP2C9*3 (rs1057910)
1075C>C
I359L
Adapted from Fohner, et al, 2013 [90, 167, 168].

Activity Change
decreased
decreased

Table 1.3. CYP2C9 Allele Frequencies
Allele

CSKT

CEU

YRI

JPT

CHB

Canadian
Inuit

Canadian
First
Nation

Central
America
(Tepehuano/
Mestizos)

rs4918758
25.0 35.8 30.1 41.3 33.7
CYP2C9*2
5.17 10.4
0
0
0
0
3.0
1-7
CYP2C9*3
2.69
5.8
0
2.3
4.7
0
6.0
1.5
rs28371689 30.77
rs1057911
2.7
5.8
0
3.4
4.4
CSKT = Confederated Salish and Kootenai Tribes (n=188 chromosomes). HapMap
populations: CEU = Utah residents with ancestry from northern and western Europe
(n=120 chromosomes); YRI = Yoruba in Ibadan, Nigeria (n=120 chromosomes); JPT =
Japanese in Tokyo, Japan (n=90 chromosomes); CHB = Han Chinese in Beijing, China
(n=90 chromosomes). Adapted from Fohner, et al., 2013 [90].
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Table 1.4. Major CYP2D6 Alleles
Allele
CYP2D6*1
CYP2D6*2
CYP2D6*3
CYP2D6*4

Protein Effect
Phenotype
None
EM
R296C; S486T
Frameshift
PM
P34S; splicing defect;
PM
S486T
CYP2D6*5
Gene Deletion
Gene deletion
PM
CYP2D6*9
2615delAAG
K281del
IM
CYP2D6*10
100C>T; 4180G>C
P34S; S486T
IM
CYP2D6*17
1023C>T; 2850C>T
Amino Acid Substitution
IM
CYP2D6*28 19G>A; 1704C>G; 2850C>T;
V7M; Q151E; R296C;
ND
4180G>C
S486T
CYP2D6*33
2483G>T
A237S
EM
CYP2D6*35
31G>A; 2850C>T; 4180G>C
V11M; R296C; S486T
EM
CYP2D6*41 2850C>T; 2988G>A; 4180G>C
R296C; splicing defect;
IM
S486T
Phenotypes denoted as: PM = Poor Metabolizer; IM = Intermediate Metabolizer.
Adapted from Fohner, et al., 2013 [90].
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37.57

0.27

20.86

1.34

0.80

1.34
0

0.27

0.53

1.07

11.23

CYP2D6*1

CYP2D6*3

CYP2D6*4

CYP2D6*5

CYP2D6*9

CYP2D6*10

CYP2D6*17

CYP2D6*28

CYP2D6*33

CYP2D6*35

CYP2D6*41

6.9 - 14.0

4.8 - 8.5

0

0 - 1.11

0.9 - 8.0

0 - 3.8

0 - 6.9

11.3- 33.4

0 - 3.20

28.6- 83.0

European

Chinese

0

0

0

0

8.6 - 45.9

0

4.1 - 7.2

0 - 0.77

0

1.84 - 14.9 0.51 - 2.60

0.38 - 1.10

13.7 - 26.0

2.70 - 7.50

0.18 - 1.15

2.80 - 6.90

3.86 - 7.8

0.18 - 0.60

2.2 - 4.0

0

0 - 0.21

22.4 - 64.1

0 - 1.27

2.54 - 9.60

0 - 1.10

0

29.7 - 83.0 27.0 - 93.8 18.0 - 38.4

African Japanese
American

2.30

6.7 - 8.3

0

89.10

3.0

3.0

0

68.0 - 94.0

2.54

0 - 10.20

0 - 12.45

0.80 - 4.60

0.6 - 19.4

0 - 1.44

38.8 - 99.4

Canadian Canadian
Central
Inuit
First
America
Nation
(Tepehuano/
Mestizos)

CSKT = Confederated Salish and Kootenai Tribes (n=374 chromosomes). Adapted from Fohner, et al., 2013 [90].

CSKT

Allele

Table 1.5. Major CYP2D6 Allele Frequencies

0.85

1.80 - 7.10

0

0 - 4.20

3.6 - 17.8

0

39.9 - 84.9

South
America
(Embera/
Mapuche)

Table 1.6. Major CYP3A4 alleles
Allele

Nucleotide
Change
CYP3A4*1B (rs2740574)
-392A<G
CYP3A4*1G (rs2242480)
20230G>A
CYP3A4*2 (rs55785340)
15713T>C
CYP3A4*3 (rs4986910)
23171T>C
CYP3A4*8 (rs72552799)
13908G>A
CYP3A4*12 (rs12721629)
21896C>T
CYP3A4*13 (rs4986909)
22026C>T
CYP3A4*15A (rs4986907)
14269G>A
CYP3A4*17 (rs4987161)
15615T>C
CYP3A4*18 (rs28371759)
20070T>C
CYP3A4*22 (rs35599367)
15389C>T
Adapted from Fohner, et al, 2013 [90, 135, 168].

Protein Effect
promoter
intronic
Ser222Pro
Met445Thr
Arg130Gln
Leu373Phe
Pro416Leu
Arg162Gln
Phe189Ser
Leu293Pro
intronic

Change in
Activity
decreased
decreased
decreased
none
decreased
both
decreased
nonfunctional
both
both
decreased

Table 1.7. Major CYP3A4 Allele Frequencies
Allele

CSKT

CEU

YRI

JPT

CHB

Central America
(Tepehuano/
Mestizos)
8.0 – 8.8

CYP3A4*1B
2.20
3.0
72.0
0
0.3
CYP3A4*1G
26.81
8.3
88.9
29.7
28.0
CYP3A*2
0
0
0
0
0
CYP3A4*3
0
1.2
0
0
0
CYP3A4*8
0
0
0
0
0
CYP3A4*12
0
0
0
0
0
CYP3A4*13
0.60
0.4
0
0.6
1.2
CYP3A4*15A
0.68
0
2.84
0
0
CYP3A4*17
0
0
0
0
0
CYP3A4*18
0
0
0
1.7
0
CYP3A4*22
2.44
5.29
0
0
0
rs2687116
2.27
1.8
74.4
0
0
CSKT = Confederated Salish and Kootenai Tribes (n=188 chromosomes). HapMap
populations: CEU = Utah residents with ancestry from northern and western Europe
(n=120 chromosomes); YRI = Yoruba in Ibadan, Nigeria (n=120 chromosomes); JPT =
Japanese in Tokyo, Japan (n=90 chromosomes); CHB = Han Chinese in Beijing, China
(n=90 chromosomes). Adapted from Fohner, et al., 2013 [90, 121, 169].
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Table 1.8. Major CYP3A5 Alleles
Allele

Nucleotide
Protein Effect
Change
CYP3A5*3 (rs776746)
6986A>G
intronic
CYP3A5*6 (rs10264272)
14690G>A
truncation
CYP3A5*7 (rs76293380) 27131_27132insT
frameshift
rs15524
31611T>C
3’ UTR
Adapted from Fohner, et al, 2013 [90, 135, 168].

Change in Activity
nonfunctional
nonfunctional
nonfunctional

Table 1.9. Major CYP3A5 Allele Frequencies
Allele
CSKT
CEU
YRI
JPT
CHB
CYP3A5*3
92.27
94.1
15.0
73.3
66.3
CYP3A5*6
0
0
16.8
0.6
1.2
CYP3A5*7
0
0
0
0
0
rs15524
10.64
4.0
72.6
28.5
33.7
CSKT = Confederated Salish and Kootenai Tribes (n=188 chromosomes). HapMap
populations: CEU = Utah residents with ancestry from northern and western Europe
(n=120 chromosomes); YRI = Yoruba in Ibadan, Nigeria (n=120 chromosomes); JPT =
Japanese in Tokyo, Japan (n=90 chromosomes); CHB = Han Chinese in Beijing, China
(n=90 chromosomes). Adapted from Fohner, et al., 2013 [90, 121, 169].
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Figure 1.1. Cytochrome P450 Cycle. Adapted from [170].
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Figure 2.2. SNP Gene Map A. CYP3A4. B. CYP3A5. Exons are denoted by boxes
and introns as lines. Adapted from Lamba, et al., 2002 [30, 135, 168].

B.

A.

Chapter 2: Lymphocytes as Surrogates of CYP3A Drug
Metabolism
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2.A. Introduction
CYP3A4 is responsible for the metabolism of 50% of drugs currently on the
market [129, 142, 143]. It is reported that 66 - 90% of the interindividual variability
in CYP3A4 activity is a result of genetic variability [154]. While there are many
identified SNPs, several do not have conclusive evidence linking them to the
interindividual change [168]. CYP3A4*1G is an SNP located within intron 10
(20230G>A) and has conflicting reports of its impact on CYP3A4 activity. Most
reports show a decrease in activity [116-120], however, some show an increase
in function [137-139].

Genetic variants can be measured in vivo, where CYP activity is measured via
administration of probe drugs or radiolabeled drugs [171, 172]. Probe drugs are
metabolized by a single drug-metabolizing enzyme and are administered to
identify the function of that enzyme, or the change in function of the enzyme due
to the presence of a SNP. Plasma concentrations of the probe drug and
metabolites are measured to estimate various pharmacokinetic parameters [172].
Also, one could measure CYP changes in activity, protein, and mRNA levels
within liver hepatocytes or microsomes after performing a liver biopsy [173, 174].
However, both methods present some considerable disadvantages. Probe drug
administration creates the risk of adverse events, multiple blood draws and urine
collection, length of time needed to collect samples from patient, and the
associated high cost [175]. Liver biopsies are not routinely performed, especially
for the purpose of the phenotyping a patient [173]. These substantial
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disadvantages associated with in vivo phenotyping presents a large barrier in
clinical practice as well as research.

Because of some of the challenges associated with existing phenotyping
methods, there is increased interest in using a more readily available tissue such
as peripheral blood cells. These cells could be used as surrogate markers of
drug metabolism or changes in drug metabolism. Peripheral blood cells are made
up of red blood cells, white blood cells, and platelets. White blood cells are made
in lymphoid tissues and include several subsets of cells: neutrophils, eosinophils,
basophils, monocytes, and lymphocytes. Lymphocytes are responsible for
recognizing foreign antigens and mounting a response [176]. There are several
advantages to measuring CYP activity in lymphocytes: no need for probe drug
administration, less invasive sampling, less time involved for the patient, as well
as less expensive to test [175]. Several CYPs have been measured in
lymphocytes, including CYP3A4 [177]. However, there are conflicting reports in
literature of the consistency in measuring CYP3A4 activity and mRNA levels and
its correlation to liver activity and expression [173, 175, 178-183].

The goal of this study was to determine the functional consequences of the
genetic variant CYP3A4*1G using lymphocyte cell lines that are wild type,
heterozygote, and homozygote for the CYP3A4*1G genotype. CYP3A4*1G
functional consequence in lymphocytes was assessed by measuring 1) mRNA by
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quantitative PCR, 2) protein levels by immunoblot detection, and 3) CYP3A4
activity using the substrate luciferin IPA.

2.B. Materials and Methods
2.B.i. Cells
B-lymphocytes were ordered from the National Human Genome Research
Institute Sample Repository for Human Genetic Research through the Coriell
Institute for Biomedical Research. Lymphocytes were selected based on
CYP3A4 and CYP3A5 genotype: CYP3A4*1/*1, CYP3A4*1/*1G, and
CYP3A4*1G/*1G; all samples were CYP3A5*1/*1. All samples were from
females. Cells were maintained in RPMI Medium 1640 with 2mM L-glutamine
and 15% FBS at 37°C and 5% CO2. They were split to a density of 200,000
viable cells/mL every third day.

2.B.ii. RNA Isolation and cDNA synthesis
RNA was isolated using the PureLink® RNA Mini Kit (Life Technologies,
Carlsbad, CA) and RNA concentration and quality was measured on a Nanodrop
spectrophotometer. PureLink® DNAse Treatment (Life Technologies) was used
during RNA extraction to digest any DNA. cDNA was immediately synthesized
using the High Capacity RNA-to-cDNA™ Kit (Applied Biosystems®, Carlsbad,
CA) on a C1000 Thermocyclyer (Bio-Rad, Hercules, CA). Samples were not
frozen and immediately underwent quantitative PCR.
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2.B.iii. Quantitative Real-time PCR
CYP3A4, CYP3A5, β-actin, and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA were measured using TaqMan® Gene Expression Assay
(Applied Biosystems®). Primer/probe pairs were: CYPA4 Hs00604506_m1;
CYP3A5 Hs01070905_m1; β-actin H99999903_m1; GAPDH Hs03929097_g1.
Taqman® probes had a reporter dye, FAM™, on the 5’ end and a nonfluorescent
quencher (TAMRA™) on the 3’ end. TaqMan® Universal Master Mix II, with UNG
was used to perform amplifications. TaqMan® probe identification and amplicon
length as well as exon location are defined in Table 2.1. All amplicons produced
are relatively short and are not expected to PCR efficiency. Probes for CYP3A4
and CYP3A5 span exons, so no genomic DNA will be amplified. cDNA template,
200 ng, underwent cycling conditions of 1 cycle at 50°C for 2 min, 1 cycle of 95°C
for 10 min, then 50 cycles of denaturation at 95°C for 15 sec and
annealing/elongation at 60°C for 1 min on an Mx3000P qPCR system (Agilent
Technologies, Santa Clara, CA). Each amplification was performed in
quadruplicate at two separate times with independent RNA isolations. Data was
normalized to housekeeping gene (ΔCt) by subtracting its Ct from the Ct of the
CYP3A4/5. Ct was defined as 10 standard deviations above average background
level. Reporter signal was normalized to a passive reference dye, ROX™,
included in the master mix.
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2.B.iv. CYP3A4 Protein Quantitation in Lymphocytes
Protein quantitation in lymphocyte was performed by immunoblot. Total protein
(10 µg) of cell lysate was added and resolved on a Tris-Hepes NH 4-20%
(NuSep, Lane Cove, Australia). Protein was transferred to nitrocellulose
membranes and blocked with 5% milk for 1 hour. The membrane incubated with
primary anti-CYP3A4 antibody (Abnova, Taipei City, Taiwan) (1:1,000 dilution) on
a rocker overnight at 4°C. Secondary anti-mouse antibody was added (1:25,000
dilution) for 1 hour at room temp. Membrane was developed using the West
Femto Kit (Thermo Scientific™, Waltham, MA) and imaged on a using an LAS3000 camera (Fujifilm, Minato, Tokyo).

2.B.v. CYP3A4 Protein Quantitation in Human Liver Microsomes
Protein quantitation in human liver microsomes was performed by immunoblot.
Total protein (10 µg) were added per HLM sample and resolved on a Tris-Hepes
NH 4-20% gel (NuSep) Protein was transferred to nitrocellulose membranes and
blocked with 5% milk for 1 hour. The membrane incubated with primary antiCYP3A4 antibody (Abnova) (1:1,000 dilution) on a rocker overnight at 4°C.
Secondary anti-mouse antibody was added (1:25,000 dilution) for 1 hour at room
temp. Membrane was developed using the West Femto Kit (Thermo Scienctific™)
and imaged on an LAS-3000 camera (Fujifilm).
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2.B.vi. CYP3A4 Activity in Lymphocytes
CYP3A4 activity was assessed in lymphocytes using P450-Glo™ assay system
(Promega, Madison, WI). Lymphocytes were counted in serum-free media and 5
x 104 – 5 x 106 cells in suspension were placed into 1.5 ml eppendorf tubes. An
equal volume of 2x P450-Glo™ substrate (Lucierin IPA) in serum free media was
added to cell suspension. Tubes were incubated at 37°C and 5% CO2. An equal
volume of Luciferin Detection Reagent was added and tubes were placed on an
orbital shaker for 15-20 min at room temp. Solution was transferred to a white,
untreated 96-well plate and luminescence detected on a SynergyMX microplate
reader (Biotek, Winooski, VT) with an integration time of 1 second/well.

2.B.vii. Data Analysis
A Tukey’s post hoc test was completed to determine differences in the qPCR
ΔCts between lymphocyte cell lines, α=0.05 (KaleidaGraph, Reading, PA).

2.C. Results
2.C.i. CYP3A4 mRNA Expression in Lymphocytes
All genes of interest were detected in all three lymphocyte cell lines, although,
CYP3A4 mRNA levels were very low as demonstrated by the high Ct values
(Table 2). Representative quantitative PCR traces of each cell line are shown in
Figure 2.1. The Cts of all genes are reported in Table 2.2 and ΔCts, CYP3A4 and
CYP3A5 normalized to housekeeping genes, are reported in Figure 2.3. ΔCts
show that the order of the CYP3A4 expression is as follows: CYP3A4*1/*1G >
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CYP3A4*1G/*1G > CYP3A4*1/*1. There is statistical significance between all
three cell lines (normalizing to β-actin: *1/*1 and *1/*1G p<0.0001; *1/*1 and
*1G/*1G p=0.002; *1/*1G and *1G/*1G p=0.031 and normalizing to GAPDH:
*1/*1 and *1/*1G p<0.0001; *1/*1 and *1G/*1G p=0.045; *1/*1G and *1G/*1G
p=0.002). With respect to CYP3A5 expression levels, CYP3A4*1/*1G also
expresses the most CYP3A5. The *1/*1G genotype expresses more CYP3A5
than the *1/*1 genotype, after normalizing to both β-actin and GAPDH, p<0.0001
for all comparisons. However, there is no significance between the CYP3A5
expression levels when controlling for either housekeeping gene between the
CYP3A4*1G/*1G and CYP3A4*1/*1 genotypes (β-actin p=0.63; GAPDH p=0.4).

To show that CYP3A4 was amplified in qPCR, and the high Ct was not due to
primer/probe degradation, the amount of cDNA added to each reaction was
diluted. Instead of adding 200 ng of total RNA to each reaction, 25 ng of total
RNA was added. Figure 2.3 shows the qPCR traces of the template dilution. The
diluted total RNA samples have a higher Ct value indicating less CYP3A4 mRNA
in the sample. Table 6 shows the Ct values of each gene for the different
amounts of total RNA added as well as the ratio of Cts for 200 ng to 25 ng. These
ratios were similar across genes, confirming that the Cts measured are not due to
probe degradation.
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2.C.ii. CYP3A4 Protein Expression in Lymphocytes
Immunoblots of each lymphocyte cell line were performed to quantify CYP3A4
protein content. In contrast to the qPCR data, western blot quantification (Figure
2.4) shows that CYP3A4*1G/*1G has the most expression, followed by
CYP3A4*1/*1G. Wild-type CYP3A4 had no detectable protein, however, a high
molecular weight band was detected. To understand this high molecular weight
band, we ran another immunoblot in human liver microsomes of the same
genotypes (Figure 2.4). The high molecular weight band was not detected in any
genotype of the human liver microsomes and it appears to be specific to
lymphocytes.

2.C.iii. CYP3A4 Activity in Lymphocytes
Next, CYP3A4 activity in lymphocytes was measured. Cells were first incubated
with 3 µM substrate for 15 min with zero activity measured. Next, time was
increased to 1 hour incubation at the same substrate concentration and, again,
measured zero activity. Finally, cells were treated with 25 µM substrate for 3
hours; the rate measured was negligible.

2.D. Discussion
There is interest in finding a more accessible tissue as a surrogate of drug
metabolism in the liver. Blood sampling is minimally invasive, low risk, and
relatively unlimited. However, CYPs are not highly expressed within lymphocytes
and there are several contradicting studies as to their metabolic relevance. Our
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goal was to establish whether immortalized lymphocytes, with defined CYP3A4
and CYP3A5 genotypes, could be used to determine the functional consequence
of the CYP3A4*1G SNP.

Several groups have been able to quantify CYP3A4 in lymphocytes. Sempoux et
al. and Starkel et al. showed that CYP3A proteins were detectable in Blymphocytes by immunoblot and or immunohistochemistry [184, 185]. Nakamoto
et al. were able to detect CYP3A4 mRNA in all samples of lymphocytes (n=8) by
quantitative competitive (QC) RT-PCR. They were also able to measure a
statistically significant level of induction after oral administration of rifampin.
Along with an increase of mRNA content, this group also found an increase in the
ratio 6β-hydroxycortisol to cortisol, indicating an increase in CYP3A4 liver activity.
These data imply that lymphocytes can indeed be used as a surrogate for liver
activity [180]. However, this group did not use primers that spanned exons,
causing amplification of any DNA present in the sample. This could result in more
CYP3A4 measured than is actually present as cDNA. Krovat et al. and
Nowakowski-Gashaw et al. were able to detect CYP3A4 in lymphocytes using
QC-PCR [182, 186]. Gashaw et al. was also able to measure CYP3A4
expression in all samples and also found a weak, but significant, correlation
between mRNA content in lymphocytes with alprazolam clearance [173].

Some groups have been able to detect CYP3A4 but were unable to correlate
levels of expression with CYP3A4 function in the liver. Finnstrom et al. reported
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measuring CYP3A4 expression at relatively high levels. They used qPCR with
16.7 ng total RNA and a Ct cutoff value of 38, which corresponds to 1000
molecules. Most lymphocyte traces had Cts between 33 and 37, however, they
did not show housekeeping, normalizing gene traces. They were unable to find a
correlation between liver and lymphocyte CYP3A4 expression [179]. Haas et al.
also were able to measure CYP3A4 mRNA in all samples but found a poor
correlation between lymphocyte mRNA and total body enzyme function. However,
Koch et al. and Siest et al. were unable to detect CYP3A4 in lymphocytes and
used up to 40 ng of total RNA per reaction [178, 181]. Several of these studies
measured CYP3A4 in lymphocytes after induction. Weak correlation, if any was
found, possibly due to the mechanism of induction. Rifampin activates pregnane
X receptor (PXR), which binds to the promoter of CYP3A4. However, PXR
expression is tissue-specific and also exhibits interindividual variability [175]. This
could explain the negative findings after induction. None of these studies
investigated the impact of CYP3A4 genotypes and its expression in lymphocytes
with CYP3A4 liver function.

We were able to measure the relative quantities of CYP3A4 in all lymphocyte cell
lines. The Ct values of CYP3A4 indicate very low levels present in lymphocytes.
CYP3A4*1/*1G heterozygotes had not only the most CYP3A4 expression, but
also the most CYP3A5 expression, which all had the same genotype. Therefore,
CYP3A4 content between cell lines, although significant, but doesn’t appear to
be meaningful. One would expect to see a gene-dose relationship between cell

	
  

49	
  

line with the heterozygote cells expressing an intermediate level of mRNA,
making it impossible for the heterozygotes to express the most CYP3A4.
Therefore, there is some other unknown mechanism, other than the CYP3A4*1G
genotype, causing the CYP3A4*1/*1G cells to express the most CYP3A4 and
CYP3A5. Perhaps, there are unknown SNPs within the regulation pathway of
CYP3A enzymes that is causing the upregulation of both CYP3A4 and CYP3A5,
for instance, PXR.

We are confident that all Cts measured are real and not due to primer/probe
degradation. Figure 2.3 shows the qPCR curve shift to the right when less total
RNA was added. Also, the ratio Cts of the 200 ng total RNA to 25 ng total RNA is
similar across all genes. Again, indicating that measured Cts are of templates
and changes in Cts are due to changes in starting template.

In contrast to the qPCR data, protein quantification by immunoblot actually shows
CYP3A4*1G/*1G has the highest protein content, followed by CYP3A4*1/*1G,
and not detectable in CYP3A4*1/*1. This data is more in line with the gene-dose
theory with the heterozygotes expressing an intermediate amount of protein.
Interesting, the wild-type lymphocytes exhibit a larger molecular weight band that
is present at lower levels in the heterozygote and not present in the *1G
homozygote. This led us to perform another immunoblot with a more relevant
tissue, human liver microsomes (HLM), to see if this high molecular weight band
is also present. This band was not seen in any genotype of HLM samples and
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appears to be specific to the lymphocytes. It is unclear at this time what this band
is or its clinical relevance, if any. However, it is clear that it is not due to the gene
status of CYP3A4.

We were unable to measure the activity of CYP3A4 within lymphocytes using a
highly sensitive, luminescent method. Cells are incubated with luciferin IPA,
which creates luminescence after it is metabolized by CYP3A4, upon addition of
the detection reagent. This is a sensitive method to detect minimal activity within
the lymphocytes. However, regardless of length of incubation or the
concentration of substrate, negligible, if any, activity was measured.

Our study shows that lymphocytes do not appear to be a good source to
measure CYP3A4 activity in vitro. Our goal was to use lymphocytes as a
surrogate human tissue to evaluate the effects of the CYP3A4*1G SNP, however,
measurements of CYP3A4 mRNA and protein content and CYP3A4 activity in
lymphocytes suggest that they are not a reliable surrogate for liver enzyme
content and function. Our data confirm that lymphocytes are not able to be used
to identify changes in enzymes due to CYP3A genetic variation.
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Table 2.1. TaqMan® Probe Information
Protein
CYP3A4

Amplicon Length
119

Location (exons)
2-3

101

2-3

β-actin

171

1

GAPDH

58

8

(Hs00604506_m1)

CYP3A5
(Hs01070905_m1)
(Hs99999903_m1)
(Hs03929097_g1)

Primer/probes pairs where ordered from Applied Biosystems®. TaqMan® Gene
Expression Assay was used with a reporter dye, FAM™ on the 5’ end and a
nonfluorescent quencher (TAMRA™) located on the 3’ end.
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Table 2.2. Cts by Genotype
CYP3A4
CYP3A5
GAPDH
β-Actin
CYP3A4*1/*1
38.95 ± 0.616
34.02 ± 0.189 14.81 ± 0.147 15.84 ± 0.167
37.68 ± 0.259
33.85 ± 0.250 13.54 ± 0.015 14.76 ± 0.059
CYP3A4*1/*1G
38.33 ± 0.288
33.06 ± 0.126 16.68 ± 0.224 16.51 ± 0.213
36.64 ± 0.387
30.61 ± 0.214 13.84 ± 0.282 14.86 ± 0.577
CYP3A4*1G/*1G
38.85 ± 0.315
34.80 ± 0.355 16.07 ± 0.125 16.32 ± 0.200
37.29 ± 0.367
34.27 ± 0.161 14.05 ± 0.139 14.78 ± 0.154
Two qPCR runs were completed per cell line (each row represents one run). Ct is
defined as ten standard deviations above the average background level.
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Table 2.3. Cts of Template Dilution
CYP3A4
CYP3A5
GAPDH
β-actin
200 ng
38.91 ± 0.54 34.32 ± 0.28
15.79 ± 0.11
20.36 ± 0.11
25 ng
44.68 ± 1.60 39.46 ± 0.84
20.05 ± 0.21
24.89 ± 0.09
Ratio 200 ng/25 ng
0.871
0.870
0.788
0.818
Each qPCR run in quadruplicate. Ct is defined as ten standard deviations above the
average background level.
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Figure 2.1. qPCR Traces of Lymphocytes. A. CYP3A4*1/*1 lymphocytes B.
CYP3A4*1/*1G lymphocytes C. CYP3A4*1G/*1G lymphocytes. Traces (n=4) are
representative. Solid circles are CYP3A4 amplicons, empty circles are CYP3A5
amplicons, solid triangles are β-actin amplicons, and empty triangles are GAPDH
amplicons. Fluorescence (dRN) is the reporter signal normalized to a passive reference
dye, ROX™.
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Figure 2.2. CYP3A4 and CYP3A4 Normalized Expression Levels. Each gene is
normalized to housekeeping genes, as denoted in the figure legend. Lower values
correlate to more mRNA expression of the gene of interest (CYP3A4 or CYP3A5).

	
  

56	
  

CYP3A4*1G/*1G
3.5

200 ng
25 ng

3

Fluorescence (dRn)

2.5

2

1.5

1

0.5

0

-0.5
0

10

20

30

40

50

60

Cycle Number

Figure 2.3. qPCR Traces of Template Dilution. qPCR traces of 200 ng (solid circles)
and 25 ng (empty circles) of total RNA added per reaction. Fluorescence (dRN) is the
reporter signal normalized to a passive reference dye, ROX™.
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Figure 2.4. Immunoblot and Quantification CYP3A4 Protein. A. Lymphocyte
CYP3A4 immunoblot. Standards lane 1 (10 ng), 2 (5 ng), 3(1 ng), 4 (0.5 ng), 5 (0.25 ng).
Lymphocytes lanes 7 (CYP3A*1G/*1G), 8 (CYP3A4*1/*1G), and 9 (CYP3A4*1/*1).
Negative control, Sf9 insect cells, lane 10.. B. CYP3A4 protein quantitation stratified by
genotype of lymphocyte cell lines. C. HLM CYP3A4 immunoblot. Lanes 1 and 2 are
CYP3A4*1G/*1G samples, lanes 3-7 are CYP3A4*1/*1G samples and lanes 8-11 are
CYP3A4*1/*1 samples. Standards are in Lanes 13(1 ng), 14 (5 ng), and 15 (10 ng).
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Chapter 3. Effect of the Genetic Variant CYP3A4*1G
in Human Liver Microsomes
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3.A. Introduction
CYP3A4 is drug-metabolizing enzyme highly expressed in the liver and intestine
[97]. CYP3A4 metabolizes about 50% of all medications available on the market,
comprised of more than 120 different drugs from therapeutic classes that include
antihistamines, immunosuppressive agents, benzodiazepines, and HIV protease
inhibitors [99, 131]. Up to 40-fold variability has been reported in interindividual
CYP3A4 activity [112, 155, 156] and up to 90% is predicted to be due to genetic
factors [154]. Because of the huge diversity of CYP3A4 substrates, genetic
variability can have a large clinical impact in drug response and toxicity [30].
Pharmacogenomic studies aim to identify these genetic variations and determine
their resulting changes in activity.

Probe drug studies are the gold standard in in vivo phenotyping of
pharmacogenetic variation as they provide direct predictions of alterations in
pharmacokinetic parameters, however, these studies have considerable
disadvantages (discussed earlier in Chapter 1 section A.ii.). Therefore,
investigators also try to evaluate pharmacogenetic variation using in vitro
methods [187, 188]. One of these widely accepted methods is using human liver
microsomes (HLM) [189]. HLMs are generated from liver samples, obtained by
liver biopsies or organ donation. Liver samples undergo several cycles of
homogenation and centrifugation to form vesicles from isolated endoplasmic
reticulum. Because CYPs are microsomal proteins, HLMs contain concentrated
levels of CYPs. Liver microsomes enable one to make pharmacokinetic
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estimations (rate of metabolism, intrinsic clearance) that are scalable to whole
liver and whole body predictions, without the need to administer medications in
vivo and gather blood and urine samples. For instance, HLMs were first identified
to give good predictions of intrinsic clearance in rats [41, 190-192]. Correlations
were soon made between clearances measured in HLMs and those measured in
an in vivo pharmacokinetic study [187, 193, 194]. In order to best estimate
intrinsic clearance, it is important to maintain incubations conditions similar to
those seen in vivo. Specifically, incubation times need to be such that product
formation is linear (initial rate is constant) over the duration and drug
concentrations are comparable to clinical concentrations [187]. Scaling from
HLMs to whole body deviate the most when metabolism occurs in organs other
than the liver, for instance, the intestines, or when metabolism occurs by routes
other than CYP oxidation [187, 195]. This scenario would lead to an
underestimate of total clearance [187]. HLMs are commonly used in research as
well as drug development [196]. They are inexpensive, convenient, readily
available, and create reproducible data [197]. When stored at -80°C, microsomes
retain their activity for years [198].

There are disadvantages to using microsomes as an alternative for in vivo data.
Disease and medication histories of the subjects from whom the livers are
obtained are often unknown or incomplete. Disease state, such as diabetes
mellitus, can cause decreased CYP3A4 expression and activity [199]. Length of
time before organ procurement can also affect CYP expression; increased

	
  

61	
  

cytokine release, due to inflammation and infection, as well as decreased
hormone secretion leads to down regulation of CYPs [30, 154, 200].
Concurrent medications can cause inhibition or induction and need to be
incorporated into data analysis. Also, organ collection protocols, tissue storage
conditions, and microsomal preparations all can have an effect on microsomal
enzyme activity. Because of this, it has reported that in vitro interindividual
variability is larger than in vivo interindividual variability [129].

Our study aimed to investigate the any change in activity due to the CYP3A4*1G
genetic variant in vitro using HLMs that have been previously genotyped.
CYP3A4 activity in HLM was measured using a selective CYP3A4 substrate with
minimal/no substrate overlap with CYP3A5. Our goal was to make genotypephenotype associations in the HLMs to assess CYP3A4*1G activity.

3.B. Materials and Methods
3.B.i. Human Liver Microsomes
Human liver microsomes (n=324) were obtained from University of Washington,
School of Pharmacy Human Liver Tissue Bank (Seattle, WA). The University of
Washington made all human liver microsomes. Liver tissue was homogenized
using a Bead Ruptor. Homogenate was centrifuged at 15,000g for 30 min.
Centrifuge supernatant at 120,000g for 70 min. The pellet was resuspended in
wash buffer and homogenized with a glass homogenizer and centrifuged at
120,000 g for 70 min. Pellet resuspended in wash buffer with a glass
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homogenizer and stored at -80°C. Livers were genotyped in Debbie Nickerson’s
Laboratory in the Department of Genome Sciences University of Washington
(Seattle, WA). Genotyping was determined via PGRNseq Platform (University of
Washington). PGRNseq is a next-generation sequencing platform that
sequences coding regions, adjacent noncoding regions, 2kb upstream, and 1kb
downstream in 84 genes Very Important Pharmacogenes.

3.B.ii. CYP3A4 Activity in Human Liver Microsomes
CYP3A4 activity in HLMs (n=64) was determined with the P450-Glo™ kit
(Promega) according to manufacturer’s specifications. Five µg of total protein
were preincubated in microfuge tubes with 4x P450-Glo™ substrate (luciferin
IPA) and KPO4 buffer for 10 min in a water bath at 37°C. An equal volume of
2mM NADPH was added to initiate the reaction and HLMs were, again,
incubated for 10 min in a water bath at 37°C. An equal volume of Luciferin
Detection Reagent was added and tubes were placed on an orbital shaker for 1520 min at room temp. All incubations were completed in triplicate. Pooled HLMs
were used as a positive control in every incubation set (in duplicate). Solution
was transferred to a white, untreated 96-well plate and luminescence detected on
a SynergyMX microplate reader (Biotek, Winooski, VT) with an integration time of
1 second/well. Optimization of HLM incubation conditions was completed using
pooled HLM (Xenotech, Lenexa, KS).
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3.B.iii. CYP3A4 Protein Quantitation in Human Liver Microsomes
Protein quantitation was performed by immunoblot. Total microsomal protein (10
µg) was resolved on a Tris-Hepes NH 4-20% gel (NuSep). Protein was
transferred to nitrocellulose membranes and blocked with 5% milk for 1 hour. The
membrane incubated with primary anti-CYP3A4 antibody (Abnova) (1:1,000
dilution) on a rocker overnight at 4°C. Secondary anti-mouse antibody was added
(1:25,000 dilution) for 1 hour at room temp. Membrane was developed using the
West Femto Kit (Thermo Scientific™) and imaged on an LAS-3000 camera
(Fujifilm).

3.B.iv. Data Analysis
An ANOVA was performed to test the differences between the HLM genotypes in
both activity and protein quantitation, α=0.05 (KaleidaGraph). A multivariable
regression was completed to test the significance of each variable on CYP3A4
activity. Variables tested were: protein content, genotype, age, gender, race,
taking a 3A4 inducer, taking a 3A4 inhibitor, liver pathology, cause of death,
height, weight, ICU time, liver ischemia, organ trauma, smoking status liver lab
results, and pathology. Missing data was not included in the analysis (StatsPlus,
Alexandria, VA)
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3.C. Results
3.C.i Optimization of Microsomal Incubation Conditions
HLMs are precious samples, some with extremely limited protein, so we
optimized the HLM assay using commercially available pooled HLMs (Figure 3.1).
First, microsomal protein per incubation was titrated to determine the linear range
of product formation (Figure 3.1A and 3.1B); we found that product formation was
linear between 1.25 and 10 µg total protein per reaction. The substrate, luciferin
IPA, is provided from Promega in 100% DMSO, however, DMSO is a known
inhibitor of CYPs [201]. Therefore, we next optimized DMSO concentration over
a range of substrate concentrations (Figure 3.1C) and found the largest response
using a substrate concentration of 8 µM in 0.25% DMSO. Finally, we optimized
for time to assure linear product formation (Figure 3.1D) and found that product
formation is linear between 5 and 20 min. We concluded from the optimization
experiments that incubations with liver bank HLMs be carried out with 5 µg total
protein and 8 µM final substrate concentration for 10 min.

3.C.ii. Subject Demographics
Demographics are listed in Table 3.1. Males made up 56.8% and Caucasian was
the most common ethnicity at 95.4%. Other ethnicities are reported at less than
3%. At the time of writing this thesis, the only data received on genotypes was for
64 livers; 48 are wild-type (75%), 14 are heterozygote (21.9%), and 2 are
homozygote for the *1G SNP (3.1%). Medications were not reported for all
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samples, however, 12 were reported to be taking a CYP3A4 inducer (3.7%) and
18 were reported to be taking a CYP3A4 inhibitor (5.6%).

3.C.iii. Analysis of CYP3A4 Activity
Total CYP3A4 metabolic rate ranged from non-detectable to 10.3 pmol/µg
protein/min (Figure 3.2) in 324 livers, demonstrating a huge variability in the
CYP3A4 activity. Pooled HLMs were used as a positive control. The average rate
is 1.64 ± 0.30 pmol/µg protein/min, making the interday coefficient of variation
18%.

The CYP3A4 metabolic rates of 64 genotyped livers are stratified by genotype:
CYP3A4*1/*1 (n=48), CYP3A4*1/*1G (n=14), and CYP3A4*1G/*1G (n=2) (Figure
3.3). There was no statistical difference between any genotypes (p=0.519),
however, there was a trend towards increased activity in CYP3A4*1G
homozygous individuals, although numbers were small.

A linear regression analysis was performed with all data/variables reported from
the liver bank with the HLMs. All variables, including genotype and gender, did
not significantly impact the CYP3A4 rate.

3.4. Discussion
The demographics of the liver samples are not very diverse. The majority of the
samples are Caucasian (95.4%), male (56.8%), and procured from patients who
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were between the ages of 40 and 59 (32.4%) (all are independent variables).
There are few samples that are classified as Black (n=5), Asian (n=1), and
Hispanic (n=2). Therefore, it is difficult to tease out an effect from ethnicity due to
limited sample number in this liver bank. Patients on medications that induce or
inhibit CYP3A4 were also few (n=7 and 5, respectively), again, making it difficult
to find significance on its effect on CYP3A4 metabolism. Patients classified as
taking medications that induce CYP3A4 were taking, phenytoin, a strong inducer,
and patients taking CYP3A4 inhibitors were taking amiodarone and cyclosporine,
both weak inhibitors, and erythromycin, a moderate inhibitor. No donors were
taking a strong inhibitor. There were several samples that had no report of
medications, reporting of medications could have accounted for some
interindividual variability. Regardless, all variables reported had no significant
effect on the measured CYP3A4 metabolism rate in human liver microsomes.
This was a bit unexpected as it is reported that females can express up to 2-fold
higher levels of CYP3A4 in vivo [136]. Also, there appears to be a trend that liver
microsomes with higher protein contents tend to have a higher CYP3A4
metabolism rate, even after normalized to protein content (Figure 3.5). Although,
again, this is statistically insignificant when analyzed in a multivariable regression.

We next further examined the effect of only the CYP3A4*1G genotype on
CYP3A4 metabolism. The average rate was determined of each genotype and
an ANOVA was performed to identify if there was any difference between the
three average rates. This, too, was not statistically significant (p=0.51898).
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However, there is a trend toward increasing function of the CYP3A4*1G
genotype. With only 64 genotyped HLMs, only two were identified as
CYP3A4*1G/*1G. When the rest of the liver bank is genotyped and included in
the statistical analysis, there should be more homozygote *1G samples identified,
resulting in an increase in statistical power. This may help determine if there is
truly an increase in enzyme activity due to CYP3A4*1G genotype.

Our current data do not allow us to make a definite prediction of CYP3A4*1G
impact on CYP3A4 metabolism. There was no statistical significance between
CYP3A4*1G genotype and CYP3A4 expression or activity. However, at the
writing of this thesis, of the 324 microsomes with activity data, we only have
genotypes reported for 64 microsomes. When the genotypes of the other 260
genotypes are incorporated in the analysis, perhaps significance can be teased
out with the higher sample numbers and higher power. Until then, our data
suggest that CYP3A4*1G has little significance on total metabolism and does not
account for measured interindividual variability.
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Table 3.1. Human Liver Microsome Demographics
Percentage

n

Gender
Male
Female
Unreported
Ethnicity
Caucasian
Black
Hispanic
Asian
Unknown
Age
0 – 19
20 – 39
40 – 59
60 – 79
80 – 99
Unknown
Genotype
CYP3A4*1/*1
CYP3A4*1/*1G
CYP3A4*1G/*1G
Unknown
CYP3A4 Inducers
No
Yes
Unknown
CYP3A4 Inhibitors
No
Yes
Unknown

56.8%
42.0%
1.2%

184
136
4

95.4%
2.8%
0.6%
0.3%
0.9%

309
9
2
1
3

22.2%
17.3%
32.4%
20.1%
1.5%
6.5%

72
56
105
65
5
21

14.5%
4.3%
0.6%
80.6

47
14
2
261

39.8%
3.7%
56.5%

129
12
183

38.3%
5.6%
56.2%

124
18
182

Human liver microsomes demographics reported from human liver bank (University of
Washington) (n = 324).
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Figure 3.1. Optimization of CYP3A4 Activity in Pooled Human Liver Microsomes. A.
Titration curve of total protein content of pooled. B. Linear range of total protein content
titration curve. C. DMSO titration. D. Time curve completed to determine linear range of
product formation.
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CYP3A4 Interindividual Variability
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Figure 3.2. CYP3A4 Interindividual Variability Measured in Human Liver
Microsomes. 5 µg of liver microsome total protein was incubated with 8 µM luciferin IPA
for 10 minutes. Detection reagent was added and luminescence was quantitated on a
microplate reader (n=324).
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Figure 3.3. CYP3A4 Activity in Human Liver Microsomes. HLMs were stratified by
CYP3A4 genotype (CYP3A4*1/*1 n=48; CYP3A4*1/*1G n=14; CYP3A4*1G/*1G n=2).
Positive controls were run in duplicate. An ANOVA found no statistical differences
between genotype (p=0.51898).
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Figure 3.5. Relationship Between Human Liver Microsome Total Protein Content
and CYP3A4 Rate. A. Although there is no significant statistical relationship between
total protein content and CYP3A4 metabolism rate, there is a trend between higher
protein content and increased CYP3A4 rate. (n=324) B. Data points with rates greater
than 5 pmol/ug protein/min were removed (n=322) (R=0.43).
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Chapter IV: Summary and Future Directions
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The goal of my research project was to decipher the functional consequence of
the genetic variant CYP3A4*1G. I used in vitro models to assess CYP3A4 mRNA
and protein expression and activity in lymphocyte cells and human liver
microsomes.

We hoped to use lymphocyte cell lines, with the genotypes CYP3A4*1/*1,
CYP3A4*1/*1G, and CYP3A4*1G/*1G, as surrogates of CYP3A4 drug
metabolism. This convenient, limitless resource with known genotypes would
have been ideal to study the SNP of interest. Also, the ability to quantitate
CYP3A4 mRNA, protein, and activity could have huge implications in clinical field
with the ability to phenotype patients with a single blood draw. Despite using a
sensitive, luminescent detection method to measure CYP3A4 activity, we were
unable to observe CYP3A4 activity in the lymphocytes. Therefore, lymphocytes
do not make good surrogate markers for drug metabolism and cannot be used to
measure a patients’ CYP3A4 drug metabolism rate and to make any conclusions
as the functional consequence of the CYP3A4*1G genetic variant.

The second part of my research involved using human liver microsomes to
assess the functional consequence of CYP3A4*1G variant. CYP3A4 activities
were measured in 324 human liver microsomes (HLMs). At the time of writing
this thesis, only 64 of these HLMs have been genotyped: 48 were homozygous
wild-type CYP3A4*1/*1, 14 heterozygous CYP3A4*1/*1G, and 2 homozygous for
CYP3A4*1G/*1G. Although a trend was observed towards increased activity in
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the CYP3A4*1G containing livers, a multivariable regression and ANOVA both
found no significance of the CYP3A4*1G genetic variant. Until the genotypes of
the remaining HLMs are known, there is not enough power to determine the
effect of CYP3A4*1G.

In addition to incorporating the genotype of the remaining livers into the analysis,
we will also normalize to the CYP3A4 protein levels, quantified by mass
spectrometry, both completed at the University of Washington, as soon as the
data collection is completed. However, in future work, I would measure the
protein content of known CYP3A4 transcription factors, pregnane X receptor,
constitutive androstane receptor, retinoid receptor, and hepatocyte nuclear factor
in the human liver microsome samples [202, 203]. This would allow us to account
for any of the CYP3A4 interindividual variability due to increased or decreased
expression of transcription factors and may help us better ascertain any changes
in function due to genetic variations in CYP3A4.

Other studies have found that CYP3A4*1G either causes increased [137, 138,
140] or decreased [116, 118-120] clearance in vivo. These mixed results could
arise from the contribution of other CYP3A proteins. CYP3A7 may have minor
impact as it is only expressed in 10% of adults, however, it can have large impact
in CYP3A drug metabolism in those individuals as CYP3A7 has been reported to
contribute up to 40% of CYP3A content [145-147]. CYP3A5 genotype could play
a larger role in interindividual variability in CYP3A drug metabolism. In those who
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express CYP3A5, CYP3A5 makes up 50% of CYP3A content [100]. Because of
the linkage disequilibrium found between CYP3A4*1G and CYP3A5*1 found in
HapMap populations, it is difficult to identify the functional consequence of
CYP3A4*1G. However, a novel break in the linkage of CYP3A4*1G and
CYP3A5*3 has been uncovered in the Confederated Salish and Kootenai Tribes.
Due to the high CYP3A5*3 allele frequency in this population, many would carry
both the CYP3A4*1G allele and the CYP3A5*3 allele. Studying this population,
would allow us to assay for changes in CYP3A4 drug metabolism without the
contribution from CYP3A5. Therefore, our laboratory has a proposed study to
evaluate the CYP3A4*1G genetic variant in the CSKT population using an oral,
subtherapeutic dose of midazolam, a CYP3A4 probe drug. Blood and urine will
be collected to measure midazolam and its metabolite over time. This study will
shed light on the CYP3A4*1G functional consequence unlike any other study has
been able to do; we will be able to unequivocally assay for CYP3A4*1G
metabolism.

In conclusion, changes in the CYP3A4 metabolism rate due to the *1G SNP can
have wide implications, especially in Japanese, Chinese, and CSKT populations,
where the *1G allele has been reported in high frequencies [90]. Because
CYP3A4 is responsible for metabolizing up to 50% of medications currently on
the market [129, 142-144], any changes in its metabolism rate will affect the
clearance of several medications. Also, any changes in CYP3A4 metabolism
rates can be exaggerated when inherited with nonfunctional CYP3A5, like that
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seen in the CSKT population. It is important to identify the effect of the
CYP3A4*1G genetic variant to better predict pharmacokinetic and
pharmacodynamic changes to lead to increased drug efficacy and decreased
toxicity.
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